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Abstract:  
Background/objectives: It is well-established that the stimulation of immune system of 
a patient by monoclonal antibodies, adoptive dendritic cell transfer and in situ vaccines 
can enhance antitumoral effects.Despite this, the progression-freesurvival achieved by 
these methodologies provides amodest improvement over traditional cancer treatment. 
To overcome these barriers, we hypothesize that focused ultrasound (FU)in combination 
with bubble liposomes (BL) will induce cellular stress, and elicit micro-environmental 
changes to induce a potent antitumor response.The objective of the proposed project is 
to test the feasibility of BL/FU approachagainst colon cancer in vitro and in vivo.  
 
Methods:Mice bearing C26 colon cancer were treated with FUheating and BL. Flow 
cytometric analysis was conducted to understand thematuration of DCs and 
macrophages. CytoTox 96® Assay asused to determine T cell-mediated tumor cell 
lysis.Real-Time gene expression studies were conducted to identify inflammatory 
cytokines. 
 
Results: FU and BL induceddendritic cell maturation and CTL mediated lysis of tumor 
cells in vitro. Significantly enhanced infiltration of cytotoxic T-cells in colon tumor was 
observed 4-fold difference for FU/BL compared to control. Hyperthermia(~42ºC) and BL 
treatment ofRAW 264.7 macrophages induced an M1phenotype compared to control in-
vitro.  
 
Conclusion:Hyperthermia and liposomal nanoparticle treatment induce M1 
polarization.FU and BL treatment sensitizes colon carcinoma CT26 cancer cells to the 
CTLs antitumor response.This technology has the potential for improving 
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ROLE OF FOCUSED ULTRASOUND IN CANCER IMMUNOTHERAPY 
Cancer Immunotherapy 
Solid tumors therapy typically incorporates a combination of surgery, chemotherapy, and 
radiotherapy in patients. In recent years, the use ofimmunotherapeutic is also gaining 
prominence as the4thtreatment modality in cancer patients. In this approach, a patient’s 
adaptive immune system is activated to achieve clearance of occult cancerous cells.This 
is achieved via the : 1) capturing of tumor antigens bydendritic cells (DCs), 2) priming, 
activation, and expansion of T cells, and 3) T cell trafficking to tumor, and exertion of 
effector functions (Zhang, Mehta et al. 2008). In general, activation of DCs is first 
mediated by signals that are released from dying cells (adenosine triphosphate (ATP), 
high mobility proteins (HMPB1) etc.(Mellman, Coukos et al. 2011). DCs thenendocytose 
proteins and present peptides on MHC class II molecules for T cell recognition 
(Rosenberg 1999). T cells sense the tumor cell antigen through T cell receptors (TCR) 
on thecell surface to drive antitumor immune responses(Dustin, 2016). (Engleman and 
Fong 2003)(Merad, Sugie et al. 2002) (Mahoney,2015). These mechanisms can be 
disrupted in asolid tumorsby the suppressor cells (T-regulatory or Tregs), cytokines such 
as TGF-beta and IL-10 that inhibit dendritic cell (DCs) maturation. Thereby, resulting in 
tolerance to immune therapy(Inoue, Setoyama et al. 2014). Additionally, the mast cells 
can aid in the recruitment of T-reg cells in the tumors, and increase angiogenesis; both 
of which cause tumor growth.Thus, if immune therapy has to succeed, the activation of 
immune system in vivo must be discretely and precisely controlled (Perica, Varela et al. 
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2015)(Schuler, Schuler-Thurner et al. 2003). The long term goalof our project is to 
understand the mechanisms and develop new combinatorial technologies 
thatsuccessfully remove immunosuppressivemicroenvironment to result in durable 
survival responses in patients(Hoos, Eggermont et al. 2010). 
High Intensity Focused Ultrasound (HIFU) mediated combinatorial therapy 
One approach to enhancing immunotherapy can be through combinatorial 
therapy(Vanneman and Dranoff 2012).For instance, cytotoxic agents aid immunotherapy 
by activating pro-apoptotic effects in tumor cells via receptor-driven autocrine 
pathway(Ciardiello, Caputo et al. 2000). However, the use of cytotoxic agents is limited 
by toxicity and inefficient activation of anti-tumor immunity in a synergistic 
manner(Mellman, Coukos et al. 2011).In contrast to drug agents,high intensity focused 
ultrasound (HIFU) energy isa non-invasive and non-ionizing pressure wave delivery 
technology for thegeneration of mechanical and thermal effects in solid tumors(Tardoski, 
Ngo et al. 2015). Thermal effects produce cavitation, and non-thermal treatment create a 
gap between endothelial cells to increase permeability of blood vessels (Husseini and 
Pitt 2008)(Suzuki, Oda et al. 2009). HIFU immune effects are mediated by genotoxic cell 
stress and tumor antigen release thattrigger DCs maturation. Matured DCs move to 
nearby lymph nodes (LNs), and with help from CD4+ T cells stimulate CD8+ T cellsto 
promote adaptive antitumor immunity (Bandyopadhyay, Quinn et al. 2016)(Hu, Yang et 
al. 2007)(Clay, Hobeika et al. 2001). HIFU enhances proliferation of a variety of effectors 
such as monocytes, natural killer cells, and CD4+ helper T cells of type 1 origin(Blattman 
and Greenberg 2004). In particular,CD4+ T lymphocytes of TH1 originsecrete IFN-γ, and 
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IL-2. IFN-γ induces macrophages to produce IL-12 to activate cell-mediated immune 
response. IL-2 increases the viability, and quantity of T lymphocytes to promote anti-
tumor activity of CD8 T cells.  
Clinical HIFU ( 0.8–3.5 MH)treatment of tumors (Yang, Reilly et al. 1992)(Hu, Yang et al. 
2007) also increase the HSP, HSP72&73, glucose regulated protein GRP75 & 78  ATP, 
GTP, chromatin protein HMBG1, and calreticulinlevels to increase the infiltration of DCs 
in tumors (Inoue, Setoyama et al. 2014) (Deng, Zhang et al. 2010).). Specifically, 
calreticulin interacts with DCs to promote phagocytosis of tumor cells, present tumor 
antigens on MHC I & II, and release other danger signals (Mellman, Coukos et al. 
2011)(Hu, Yang et al. 2007). HIFU also mediate CD4+ non-T reg cells, CD45+ cells 
(indication for arrival of inflammatory cells), and natural Killer cells (NK cells) activation. 
Further, the application of HIFU systemically enhances the CD4+ T cells and ratio of 
CD4+/CD8+ in blood circulation in cancer patients (Wu, Wang et al. 2004). 
Current limitations of HIFU technology 
Despite the promises of HIFU in solid tumor immune modulation, it has some limitations. 
A sub-optimal HIFU treatment reduce the level of cytokine production such as vascular 
endothelial growth factor (VEGF), transforming growth factor-β1 (TGF-β1), transforming 
growth factor-β2 (TGF-β2), interleukin 6 (IL-6) and interleukin 10 (IL-10) todecrease 
immune suppressive activity in cancer patients (Zhou, Zhu et al. 2008)(Hu, Yang et al. 
2007). HIFU mediated destruction of tissue vascularitycan preventimmune cell infiltration 
for adaptive antitumor response (Bandyopadhyay, Quinn et al. 2016).Thus, an 
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appropriate balance between cell viability and cell destruction is critical toachieving 
specific cytotoxic T-lymphocytes (CTL) against solid tumors.   
We hypothesizethat Focused ultrasound combined liposomal treatment of solid tumors 
can achieve robust immune response and efficacy in vivo. The rationales for this 
hypothesis stems from the established roles of thermal and mechanical treatment of 
solid tumors in induction of cell stress, and increased burden of misfolded protein and 
antigen release. We believe that the liposome uptake by immune cell (macrophage) and 
tumor cells will disrupt immunosuppressive tumor microenvironment, and reduce 
acoustic threshold requirements to maximize cellular stress without tumor necrosis. 
Based on this, the specific aim of our project is: 
Aim 1: Investigate the immunomodulatory role of FU and liposome in vitro and in 
vivo against primary colon tumor (CT26) models 
Aim 2:Determine the impact of FU/liposome combinatorial treatment on 
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FEASIBILITY OF FOCUSED ULTRASOUND AND BUBBLE LIPOSOMES 
COMBINATION IN-VITRO AGAINST COLON CANCER CELLS 
2.1 Abstract 
Objective: The objective of this study was to:1. analyze maturation of DCs, and 2. 
determine T cell-mediated tumor cell lysis with bubble liposome and focused ultrasound 
against colon carcinoma CT26 cell lines. 
Method: Liposomes were synthesized by thin film hydration and extrusion method, and 
loaded with perfluoropentane (PFP) to generate bubble liposome (BL).CT26 cancer cells 
were treated with BL and focused ultrasound treatment for 4 min. The supernatant 
collected from cancer cells was added to dendritic cells, and the maturation was 
quantified by flow cytometry using CD11c marker. Matured dendritic cells were co-mixed 
with cytotoxic T cells isolated from spleen of mice. Then, the activated cytotoxic T cells 
were added to CT26 cells for cytotoxicity assessment usingLDH assay.  
Result: Synthesized BL were 160 nm in size.FU/BL enhanced the maturation of 
dendritic cells by 10-15% compared to controls. A 10-30% increase in CTL cytotoxicity 
for FU/BL was observed against colon cancer cell compared to controls. 






Currently, advanced colon carcinoma cancer has poor 5-year survival rates. To enhance 
therapeutic outcomes, the objective of this study was to combine FU with bubble 
liposomes for induction of cytotoxic T-lymphocytes (CTL) mediated anti-tumor immune 
response against colon cancer in vitro. Focused ultrasound generates acoustic radiation 
forces and acoustic cavitation in tumor tissues(Liu et al. 2012). Such forces induce low-
level mechanical stress and mild hyperthermia (40-45°C), possibly resulting in 
membrane perturbation without causing significant thermal injury or cell death. The 
biological effects of focused ultrasound (FU) and its effect on CTL with liposomal gas 
bubbles are yet to be demonstrated. We hypothesized that combinational treatment of 
focused ultrasound (FU) and bubble liposomes (BLs) will exert synergetic antitumor 
cancer effect by stimulating maturation of dendritic cells activation of tumor-specific 
CTLs (Pei, Pan et al. 2015). To do so, theC26 antigens specific cytotoxic T cells were 
targeted against colon cancer cells to understand specific antitumor immune response.  
 
2.3 Materials and methods 
2.3.1 Reagents 
DPPC, 1, 2-Dipalmitoyl-sn-glycero-3-phosphocholine (LP-R4-057), MPEG-2000-DSPE 
(LP-R4-039). S-lyso-PC, 1-Stearoyl-2-lyso-sn-glycero-3-phosphocholine (LP-R4-083) 
lipids were purchased from cordon pharma (USA). Recombinant 
granulocyte/macrophage colony stimulating factor (GM-CSF) was obtained from R&D 
Systems (Minneapolis, MN, USA). Fluorescein isothiocyanate (FITC)-conjugated CD11c 
were obtained from eBioScience (Bedford, MA, USA).  Mojosort mouse CD3 T cell 
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isolation kit, APC anti-mouse CD3e,PE anti-mouse CD4, FITC anti-mouse CD8a, 
PE/Cy7 anti-mouse IL-2, PerCP/Cy5.5 anti-mouse IFN-g (BioLegend,USA) were 
purchased from Biolegend. 
 
2.3.2 Synthesis of bubble liposomes (BLs) 
Liposomes were synthesized as described previously (Danny Maples et al., (2015). 
Briefly, the phospholipids (MSPC, DPPC, and DSPE-mPEG2000) were dissolved in a 
minimum amount of chloroform (CHCl3) at a molar ratio of 85.3:9.7:5.0. The solvent was 
evaporated and the resulting lipid film was hydrated in citrate buffer (pH 4.0) mixed with 
1,3-propanediol (PD; 0.65M) at 55 °C and extruded five times through double-stacked 
200 nm polycarbonate filters to yield a final lipid concentration of 50 mg/mL. A PD-10 
size-exclusion column equilibrated with 5–10 column volumes of 1x phosphate buffer 
saline (PBS) was used to remove free 1,3-PD from the outside of the liposomes. Bubble 
liposomes was prepared by loading liposomes with  Perfluoropentane (99%, Exfluor 
Research Corporation, Texas, USA) as the bubble agents using a one-step 
sonoporation method. Briefly, 2 mL of the liposomal formulations were incubated under 
continuous sonication (~20 khz) in 3 mL vials along with PFP (boiling point 30°C; 20 
μL/100 mg lipid) for 1–2 min. PFP and liposomes were kept cold prior to being 
combined, and the sonication bath was kept at 4°C to minimize PFP vaporization. Free 
PFP was removed by column purification. This method was repeated at least in triplicate 
(n = 3) for evaluation.Liposomes (LTSLs and BLs) were characterized for size (z-




2.3.4 Cell culture 
C26 cells were provided by the National Cancer Institute kindly provided.The cells were 
cultured in Roswell Park Memorial Institute medium 1640 medium (RPMI, containing 2 
mmol/L L-glutamin,10 mmol/L HEPES,100 U/mL penicillin, and 100 mg/mL 
streptomycin) supplemented with 10% fetal calf serum (FCS, Wisent Inc., Saint-Jean-
Baptiste, QC, Canada).  
 
2.3.5 FU therapy in thin walled PCR tubes 
Prior to HIFU treatment, 2*105 cells in 200µL media were gently transferred in a 0.5 mL 
thin-walled PCR tube, and placed vertically with its conical bottom aligned within the 
beam focus of the HIFU transducer as described previously by Hu et al.2012 Ultrasound 
exposures were delivered to the tube on a singlespot for 240seconds.  HIFU transducer 
had1.5 MHz central frequency, 45 mm radius and 64 mm aperture diameter with central 
opening 40 mm in diameter. The therapeutic ultrasound device was operated in 
continuous-wave mode at a specific acoustic power: acoustic power 15W, PRF 1Hz, 
duty cycle 10% to provide non-ablative FU (Liu, Hsieh et al. 2012). Following the 
treatment, cellswere centrifuged for 5 minutes at 250 G, and the supernatant PBS was 
harvested for further analysis. 
 
2.3.6 Generation of dendritic cells from bone marrow derived cells 
Bone marrow–derived cells were harvested from the femur and tibia of C57BL/6 mice 
and cultured in RPMI 1640 medium supplemented with 10% FBS in the presence of 20 
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ng/mL murine GM-CSF (R&D). Loosely adherent immature dendritic cells were 
harvested after 6 days of culture as described previously(Madaan, Verma et al. 2014).  
 
2.3.7 Confirmation of maturation of DCs by confocal microscopy 
C26 supernatant was added to the dendritic cells on day 6 post treatment. After 24h of 
treatment, the cells were transferred into 35mm MatTek well plate for  60x oil immersion 
confocal microscopy (Tan, Leong et al. 2010). All imaging was performed with constant 
acquisition and display parameters using an inverted microscope (Olympus IX81-ZDC2) 
equipped with a color CCD camera, cooled monochrome CCD camera, motorized 
scanning stage, and mosaic stitching software (Metamorph) with a 60x oil-immersion 
objective. 
 
2.3.8 Flow cytometry analysis for maturation of DCs 
CD11c was used as a marker of DC maturation. Briefly, the DCs were harvested in 
complete medium at 37°C, 5% CO2. The samples were analyzed on FACs Aria flow 
cytometer using BD FACSD via 8.0.1 software (Kim and Diamond 2007). The 
percentage of cells positive for binding was computed from the histogram plot calculated 
from triplicate measurements of each sample. Ten thousand single cell events were 
counted from each sample.  
 
2.3.9 Lactic dehydrogenase (LDH) cytotoxicity assay 
CytoTox 96 Nonradioactive Cytotoxicity assay (Promega; Madison, WI, USA) was used 
to determine T cell-mediated tumor cell lysis. Target cells were harvested washed, and 
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50 µL/well was plated in a 96-well plate. T-cells pulsed with DCs were added at different 
effector: target cell(C26 cells)  ratio of 1:10, 1:5, 1:2.5 for 4 hours, at 37 C. 50µL of 
supernatants were harvested and measured for LDH activity following the 
manufacturer's protocol. Controls for spontaneous LDH release in effector and target 
cells, as well as target maximum release, were prepared simultaneously. Cytotoxicity 
assay (%) was calculated by the formula:  
(Experimental-Effector Spontaneous-Target Spontaneous) / (Target Maximum-Target 
Spontaneous) *100. 
 
2.3.10 Statistical analysis 
The results were analyzed using Graphpad6.0 (GraphPad Software Inc.). Multiple 
groups were analyzed by analysis of variance (ANOVA) followed by pairwise 
comparison. P<0.05 was considered statistically significant. Data are expressed as 
mean ± standard deviation (SD).  
 
2.4. Results 
2.4.1 Validation of size and zeta potential for BL 
The hydrodynamic diameter of BL was 160nm size and zeta potential was -48.95mV 
(Fig 1 and Table 1). The synthesized BLs was stable in an aqueous environment and 
exhibited no visual evidence of particle accumulation at the time of treatment. 
 
2.4.2 Combination of FU and BL stimulated the maturation of DCs 
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FU or BL alone caused ~ 5%, and FU/ BL combination induced ~8-10% maturation of 
DC, and these were significantly greaterthan the control (Fig 4 and Table 2). These 
findings were confirmed by the confocal microscopic studies where an extended 
dendrites on matured dendritic cells compared to the non-matured cells was noted (Fig. 
3). 
 
2.4.3 Combination of FU and BL stimulated C26 cell specific CTL antitumor 
response 
CTLs co-incubated with C26 supernatant treated DCs were added to C26 cancer cells in 
a 1 in 10 ratio to assess their activation status and tumor cell killing ability. FU+BL 
combination resulted in 40% killing of C26 cancer cells by the CTLs (> 4-fold than the 




Colon cancer is the third leading cause of death in cancer patients. It is poorly 
responsive to the conventional therapies due to the aggressive and invasive properties. 
These tumor cells have immune suppressing and escape mechanisms and 
respondpoorly to chemotherapy, and radiotherapy. The activation of immune cells 
namely dendritic cells which form the bridge between the innate and the adaptive 
immunity and cytotoxic T lymphocytes which have the tumor cell killing ability can 
complement the current limitation of conventional anticancer treatments approaches. 
The objective of this study was to assess the ability of FU+BL combination to generate 
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C26 specific cytotoxic T cell mediated response in vitro. We developed BL by film 
hydration technique which resulted in about 150-170 nm sized homogeneous unilamellar 
population. Importantly, the encapsulation of the bubble agent did not affect the stability 
of the liposomes up to 24 hours. Treatment of C26 tumor cells with FU+BL likely induced 
thesecretion of soluble antigens. This was evidenced by an ability of cell supernatants to 
activate dendritic cells by ~5-10% compared to untreated controls (Fig. 3 and 4). 
Additional studies on methods determine the specific soluble antigens released from the 
tumor cells after FU+BL therapy can shed more light on the signaling molecules involved 
in this process. Regardless, the T-cell activated with the supernatants from FU+BL 
therapy stimulated cytotoxic killing of C26 cells. The ability of cytotoxic T cells to kill 
tumor cells was assessed by lactate dehydrogenase assay (LDH). LDH is a cytosolic 
enzyme that is release in to the media from damaged cells as biomarker for cellular 
cytotoxicity and cytolysis. While the presence of FU or BL alone did not cause any 
significant change in tumor cell killing ability of cytotoxic T cells, co-incubation of the 
FU/BL activated T cells caused significant tumor cell killing (Fig. 5).  Thus, our in vitro 
data suggest thetheBL/FU combinatorialtherapy may hold potential as an adjuvant to 




Fig 1: BL size analysis in DLS. 
 






Fig 4: Flow cytometry evaluation ofdendritic cell maturation following treatment with FU, 
BL, and BL/FU 
 
Fig 5: CTL-mediated colon cancer celllysis. Significantly enhanced killing of cancer cells 
was noted with FU/BL combination. 
 
 
Table 1. Size, polydispersity and zeta potential of BL at 25°C  
Liposome Size (nm) Polydispersity Zeta potential (mV) 
mean SD mean SD mean SD 
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FOCUSED ULTRASOUND AND BUBBLE LIPOSOMES IMMUNOMODULATION IN 
MOUSE COLON CANCER  
3.1 Abstract 
Background: Focused ultrasound can exert thermal ablation, acoustic cavitation, and 
immunomodulation. We hypothesize that immunomodulation with sub-lethal mild 
hyperthermia and Bubble liposomes (BL) will increase cross presentation of tumor 
antigens by DCs and activation of tumor-specific CTLs. The objective of this study was 
to investigate BL/hyperthermia combination in a mouse model of colon cancer. 
Methods:Thermometry during focused ultrasound treatment was estimated by inserting 
a temperature sensor in a vial plus/minus BLs. C26 tumors was subcutaneously induced 
in the thigh region of mice. BL were administered intravenously, and 4min HIFU 
treatment were administered with Alpinion HIFU system. The ratio of CD4+/CD8+ cells 
in tumor and volume were analyzed on day 10-post treatment. 
Results: Results indicated an average 1°C temperature risein BL containing tube 
compared to FU treatment alone. Both FU and FU + BL delayed tumor growth compared 
the other treatment groups, however,   FU survival rates were not different than FU/ BL 
combination. 
Conclusion: Our animal study demonstrated that FU or FU/BL induces systemic 





HIFU temperature exposure cause HSP70 expression and misfolded protein synthesis 
in the tumor cells (Guha et al. 2012). However, it is not clear whether the adaptive 
immune responses can be impacted with increasing temperatures (Bandyopadhyay, 
Quinn et al. 2016). There is some evidence that IFN-γ secreting T cells areinduced in 
relatively higher numbers with non-thermal mechanical HIFU than thermal treatment. 
The mechanical and thermal effects of HIFU therapy can be controlled by optimizing the 
HIFU parameters such as pulse duration time, pulse repetition rate, number of pulses, 
and transducer voltage. The objective of this study was to optimize the HIFU parameters 
and understand the mechanism of mechanical and thermal treatment of colon tumors on 
the immune cell infiltration (CD3+, CD4+, CD8+, IFN-y, IL-2) in blood and tumors2-3 
weeks after treatments. 
3.3 Methods 
3.3.1 Optimization of FU for mechanical and thermal effects  
200uL of water, and E-LTSL was transferred into a PCR tube and exposed to focused 
ultrasound treatment. During treatment, temperatures in the vials were measured with  
T-type thermocouples(diameter 200µm)(Watanabe, Kakuta et al. 2005). Temperature 





3.3.2 Generation of mouse tumor model in Balb/c mice 
C26 cell lines cultured in a 75cm2 flask to 80-90% confluence wastrypsinized with 2mL 
trypsin. After 2-3 min of trypinization, 4-5mL of complete RPMI was added to the cells, 
and the cell suspension was transferred to a 15mL tube and centrifuged at 1000 rpm for 
10 minutes at 4ºC. The supernatant was discarded and 10 mL of ice cold PBS added to 
the cell pellet and centrifuged. The cells were suspended into PBS by gentle pipetting. 
The cell viability was determined by trypan blue staining. The number of cells was 
determined using a hemocytometer as given below: 
No. of cells per mL = (cell count from four chamber/4) ∗ 2 ∗ (104) 
                     2 is the dilution factor (1:1 trypan blue dilution) 
Basedon the cell count, the cell pellet was diluted with PBS to achieve a final 
concentration of 0.5*106 cells/50uL. Next, Balb/c mouse was inoculated with 50uL 
injection of the single cell suspension (0.5*106/50uL) in the right flank region. 
3.3.3 FU+BL treatment  
FU was targeted into the center of tumorfor 240 seconds following BL injection (100µL; 
40ug/mL concentration) Acoustic coupling was provided by degassed water. The 
therapeutic ultrasound device was operated in continuous-wave mode using the 
following parameters: 1)Mechanical focused ultrasound (MOFU):acoustic power: 15W, 
PRF: 1Hz, duty cycle: 10%; 2) Thermal focused ultrasound (TOFU): acoustic power: 
15W, PRF: 1Hz, duty cycle: 10%.Control groups includedSaline, BL, MOFU, TOFU, 
32 
 
MOFU+BL, and TOFU+BL.Tumor bearing mice were monitored tumor volumesupto 21 
days. 
3.3.4 Samplecollection and processing for flow cytometry 
Blood was collected in EDTA tubes from mice by cardiac puncture (10uL of 0.5 M EDTA 
for 1mL of blood). The blood was diluted 2-fold with PBS. Next,Ficoll solution was added 
to thediluted blood, mixed, and centrifuged at 800 g for 30 minutes at 25º C. The cell 
layer at the interface between PBS and Ficoll solution was collected for isolation of 
CD3+ cells. The cell layer was washed with 0.5mL of PBS containing 2% BSA & 2mM 
EDTA. In contrast to blood, the harvested tumor werechopped into < 3mm pieces, 
suspended in 5 mL of dissolution solution containing RPMI with 5% FBS and 300uL of 
collagenase (200 U/mL) type I (Roche Diagnostics, Germany) and incubated at 37 °C for 
30 min. The suspension was vortexed every 10 min during the incubation. After 
incubation, the cell suspension was passed through a 70 μm cell strainer (Falcon, USA) 
and centrifuged for 300G for 5 minutes. The supernatant was discarded, and the cells 
were processed further for flow analysis. 
 
3.3.5 CD3 T cell Isolation 
The cells from 3.3.4 was incubated with Biotin-antibody cocktail containing Biotin 
Ly6G/Ly6C (Gr1), CD45R/B220, CD49b, CD19, CD11b, CD24, TER119/ Erythroid (10 
μL of antibody cocktail for 1x107 cells in 100 μL of PBS)for 15 min inice. Then, 
Streptavidin nanobeads (10 μL of streptavidin nanobeads for 1x107 cells in 100 μL of 
PBS) were added and the cells were incubated for 15 minutes on ice. Next, PBS was 
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added to the above cell suspension and kept in amagnet for 5 min. The magnetically 
labeled non CD3+ T cell fraction was isolated using the magnetic separator, and finally 
theCD3+ T cells were collected by decanting the liquid in a clean tube.  
 
3.3.5 Staining of samples with antibody for flow cytometry analysis 
The CD3+ cells isolated from blood and tumor were labelled with CD3+ antibody APC 
(5uL of 0.2 mg/mL for 1*106 cells in 100uL). This cell suspension was split into three 
tubes for labelling with different antibodies as follows: Tube1: CD4+ and CD8+, Tube2: 
IL-2 and IFN- γ; Tube 3: CD3+ as a control. Briefly, CD4+ PE (5μL of 0.2 mg/mL for 
1*106 cells) and CD8+ (1uL of 0.5 mg/mL for 1*106 cells) antibodies were added to the 
Tube 1, vortexed and mixed well. This suspension was centrifuged at 300 G for 5 min. 
The supernatant was discarded. The cell pellet was washed with 500 μL of PBS and re-
suspended in 500 μL of PBS for flow cytometry analysis. For labelling with IL-2 and IFN- 
γ antibodies, the CD3+ cell suspension in the Tube 2 was fixed with twice the volume of 
4% Paraformaldehyde for 15 min, and centrifuged at 300G for 5 minutes. The 
supernatant was removed, and the cell pellet was incubated in 500μL permeabilization 
buffer for 5min, centrifuged at 300G for 5 minutes, and supernatant was discarded.   At 
this step, 0.65 μL of 0.2 mg/mL of IL-2 and 0.5 μL of 0.2 mg/mL of IFN- γ antibodies 
were added to the cell pellet, kept for 15 min incubation at room temperature, 
centrifuged at 300G for 5 minutes.  The cell pellet was washed with 500 μL of PBS and 
re-suspended in 500 μL of PBS for flow cytometry analysis. Samples were analyzed 




3.3.7 Statistical analysis 
The results were analyzed using Graphpad6.0 (Graph Pad Software Inc.). Multiple 
groups were analyzed by analysis of variance (ANOVA). P<0.05 was considered 
statistically significant. Data are expressed as mean ± standard deviation (SD).  
 
3.4 Results 
3.4.1 Optimization of FU parameters 
FU parameters caused no change in temperature with mechanical MOFU.TOFU 
treatment increased temperatures by 42- 45 °C in thetubes (Fig.7). Increase in 
temperature was power dependent. A 6-9 °C elevation in temperature was observed 
following an increase from 6 to10-12.5 W.  
 
3.4.2 Immunomodulation of tumors with FU+BL 
MOFU alone didn’t impact the CD4+/CD8+ ratio in tumor and blood, and 
MOFU/BLincreased the ratio by 2-fold in the blood. In contrast, thermal focused 
ultrasound(TOFU+BL) showed a modest increase (~0.5 fold) in CD+/CD8+ ratio 
compared to saline treated. In all treatments,IFN-y and IL-2 level blood levels 
weresignificantly altered compared to theuntreated control (Fig. 9). 
 
3.4.3. Tumor volume 
Mice were dived into 6 groups. 1)Saline 2)BL 3)MOFU 4)MOFU+BL 5)TOFU 
6)TOFU+BL. Tumor volumes were measured thrice weekly using Vernier calipers along 
with physical activity. Our treatment group mice MOFU, MOFU+BL, TOFU,T OFU+BL 
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showed 500mm3, 450 mm3, 680 mm3, 550 mm3  respectively (Fig. 8). Tumor volumes 
were taken over 21 days, and calculated through formula V=L*W*W/2, where V is tumor 
volume, W is tumor width, L is tumor length and it showed reduction in tumor growth 
compared saline control group. 
 
3.5 Discussion 
Here we compared MOFU and TOFU immune effects in colon cancer. MOFU didn’t 
increase temperature, and likely was non-cytotoxic in vivo. In contrast, TOFU caused 42-
45°C temperature elevation with the selected HIFU parameters. In prior research,Saha 
et al demonstrated that low intensity focused ultrasound reduced tumor growth 
significantly in mice model(Saha, Bhanja et al. 2014). However, our study suggests that 
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LIPOSOME AND HYPERTHERMIA TREATMENT OF MACROPHAGES INDUCES AN 
M1 POLARIZATION 
4.1 Abstract 
Background: Demonstration of the intrinsic impact of lipid nanomaterial uptake on 
macrophage polarization mechanisms can broaden their application for 
immunotherapeutic applications. Also, its combination with hyperthermia treatment (40-
45ºC) will provide new insights on the potential of combinatorial immunotherapies 
Methods: Liposomes were prepared by hydration of lipid film followed by the extrusion 
method and hyperthermia treatment of macrophage cell was performed using a water 
bath method as described previously. Flow cytometry analysis for CD86 and Cd206 and 
gene expression analysis were performed for pro-inflammatory (IL1-beta, TNF-α, IL6) 
and anti-inflammatory (IL10) cytokines. 
Results: Results indicated that the CD86 protein expression was 3%, 30% and 10% for 
control, heat and liposome + 42°C, liposome + 45°C respectively.  In contrast, the 
expression of CD206 increased by 1% compared to untreated controls 
Conclusion: our novel concept of liposome combined hyperthermia therapy of 
macrophages provides new insights on ways to spatially control the macrophage 




                  The use of body’s own immune system to target cancerous cells is rapidly 
emerging as an important modality for cancer prevention and treatment. Immune-
mediated targeting of cancerous cells includes various strategies such as adoptive 
transfer of activated T-cells, vaccines, or the removal of the immunosuppressive 
environment in the solid tumor(Farkona, Diamandis et al. 2016). A variety of 
inflammatory cells including tumor-associated macrophages (TAMs), myeloid derived 
suppressor cells, and lymphocytes have been linked to tumor immunosuppression. Of 
these, TAMs are the most abundant inflammatory cells of the tumor microenvironment, 
amounting to 50% of the tumor mass. TAMs are present at all stages of tumor 
progression and can be classified into two phenotypes: M1 (classical activated) and M2 
(alternatively activated pro-tumor) (Zhou, Zhang et al. 2017). In a solid tumor, TAMs 
demonstrating an M2-like phenotype has shown to cause invasion, metastasis, drug 
resistance and the emergence of cancer stem cells (Mielgo and Schmid 2013). 
Alternatively, the activation and recruitment of M1 macrophages were found to correlate 
well with antitumor immunity and improvement in the therapeutic efficacy of 
chemotherapeutics through reduction of drug resistance (especially in pancreatic and 
lung tumors) (Beatty, Chiorean et al. 2011, Yuan, Hsiao et al. 2015).  Thus, the 
reprograming and enhanced infiltration of TAMs with an M1 phenotype or induced 
expression of M1 gene or cell surface proteins in tumor microenvironment can be a 
critical step in improving response to therapy in solid cancer. 
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                   We hypothesized that the macrophage phenotype can be modulated by 
nanoparticle uptake and hyperthermia (40-45ºC) treatment. The motivation for this idea 
stemmed from recent observation of an induction of pro-inflammatory immune response 
with an M1 phenotype following phagocytosis of iron-oxide nanoparticles (Mayer, 
Dougherty et al. 1997, Miller, Zheng et al. 2015). What is not known is whether the M1 
induction is strictly dependent on iron-oxide phagocytosis by the macrophages, or 
occurs independently of nanoparticle particle chemistry.To address this question, our 
objective was to perform a comprehensive analysis of macrophage polarization 
mechanism following hyperthermia/liposome treatment. Although multiple types of 
nanoparticle (NP) platforms (iron oxide, silica, gold, silver, polymers, liposomes etc.) are 
currently under development, and each has a unique profile of advantages, limitations, 
we chose liposomes to investigate our hypothesis for multiple reasons. The physical 
properties and tumor drug-delivery capabilities of stealth and thermosensitive liposomes 
have been well-characterized in patients (Allen and Cullis 2013, Arranja, Pathak et al. 
2016). Long circulating PEGylated stealth liposomes (e.g. Doxil) accumulate selectively 
in extravascular spaces of tumors to enable slow drug release via enhanced 
permeability and retention (EPR) mechanisms(Drummond, Meyer et al. 1999, O'Brien, 
Wigler et al. 2004, Manzoor, Lindner et al. 2012, Gonzalez-Martin and du Bois 2016), 
while systems such as low temperature-sensitive liposomes (LTSL) enable triggered 
release of drugs within tumor blood vessels at hyperthermia range temperatures mildly 
elevated above normal body temperature (>40°C)(Boissenot, Bordat et al. 2016). Thus, 
liposomes are excellent nanocarrier for drug delivery. Additional demonstration of the 
intrinsic impact of lipid nanomaterial uptake on macrophage polarization mechanisms 
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can broaden their application for immunotherapeutic applications. Also, its combination 
with hyperthermia treatment (40-45ºC) will provide new insights on the potential of 
combinatorial immunotherapies (Zanganeh, Hutter et al. 2016). Data suggest that 
liposome/hyperthermia treatment impacts macrophages physiology, and this 
phenomenon can assist with novel nano immunotherapeutic development. 
 
4.3 Material and methods 
4.3.1 Synthesis of liposomes 
Lipids were prepared by hydration of lipid film followed by the extrusion method 
described previously(Senavirathna, Fernando et al. 2013). Briefly, three phospholipids 
(MSPC, DPPC, and DSPE-mPEG2000) were dissolved in a minimum amount of 
chloroform (CHCl3) at a molar ratio of 85.3:9.7:5.0. The solvent was evaporated and the 
resulting lipid film was hydrated in phosphate buffered saline (PBS) at 55°C and 
extruded five times through double-stacked 200 nm polycarbonate filters to yield a final 
lipid concentration of 50 mg/mL. A PD-10 size-exclusion column equilibrated with 5–10 
column volumes of 1x phosphate buffer saline (PBS) was used to remove free 1,3-PD 
from the outside of the liposomes.  
4.3.2 Characterization of liposomes 
Liposome was characterized for size, polydispersity index and zeta potential using a 
dynamic light scattering (DLS) instrument (Brookhaven Instruments, Holtsville, NY). 
Briefly, samples were diluted by adding 20 μL of liposomes to 1.5mL of PBS or 
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deionized water in a cuvette, and an average of three measurements was taken to 
determine the mean size (± SEM) and zeta potential of the nanoparticles. 
4.3.3 Cell Culture 
RAW 264.7 macrophages were grown in tissue culture flasks using Dulbecco Modified 
Eagle Medium (DMEM) cell culture medium supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin–streptomycin at 37°C with 5% CO2 in an incubator. 
Macrophages were harvested at 70–90% confluency, and seeded a rate of 1x106 cells/2 
mL onto 6 well cell culture plates. Prior to the experiment, the culture medium was 
discarded and cells in the wells were incubated with fresh serum free DMEM medium. 
Likewise, B16F10 cells were grown in DMEM supplemented with 10% FBS and 1% 
penicillin–streptomycin at 37°C with 5% CO2 in an incubator for MTT assay. 
4.3.4 Hyperthermia set-up for cell exposure 
Hyperthermia treatment of macrophage cell was performed using a water bath method 
as described previously (Tagami, Ernsting et al. , Kong, Anyarambhatla et al. 2000). 
After receiving liposome treatment for 15 minutes, the culture plates containing 1x106 RAW 
264.7 macrophage cells/well were placed in a water bath set to ~37, 42, and 45C for 
15min.Rise in temperature during hyperthermia treatment was confirmed by placing a 
fiber-optic temperature sensor in the water bath. Upon completion of hyperthermia 
treatment, culture plates were returned to 5% CO2 incubator at 37C for efficacy or 
macrophage polarization studies. 
4.3.5 Cytotoxicity assessment of heat against macrophages 
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An in-vitro homogeneous, colorimetric method for determining the number of viable cells 
using the MTT Non-Radioactive Cell Proliferation Assay (Promega, USA) was used to 
determine any cytotoxic effects of LTSL upon hyperthermia treatment. Briefly, ~10 x 103 
cells suspended in 100 µL of DMEM were seeded in 96-well plates and incubated for 24 
hours at 37°C in a 5% CO2 atmosphere following treatment with liposomes at an 
equivalent dose of 10µM of Dox at 37, 42, and 45C for 15min along with untreated 
control. Following this, the culture media was discarded, and the cells in each well were 
washed with PBS and re-suspended with 100 µL of cell culture media. Then 10 µL of 
MTT reagent solution was pipetted into each well, and the plates were incubated for 4 
hours at 37°C in a humidified 5% CO2 atmosphere. The absorbance at 540 nm was 
recorded using a 96-well Elisa plate reader.    
4.3.6 Confocal Microscopy of liposome uptake 
To confirm liposome uptake of macrophages, a fluorescent methodology was developed. 
Briefly, a thin film of LTSLs (lipid composition: DPPC, MSPC, DSPE-mPEG2000, and 
Coumarin-6 at a molar ratio of 84.3:9.7:5:1) was prepared as described in section 2.2 
and hydrated and extruded with 2 mL of PBS for 15–30 min at 55°C. Prior to the 
experiment, 1 x 106RAW 264.7 macrophage cells in matTek well plate 10-mm diameter 
microwells of 35-mm petridishes (MatTek Corporation, USA). were washed with 1 mL of 
PBS, added with 6uL/well of fluorescent liposomes (matching a clinical dose of lipids) 
dispersed in DMEM supplemented with 10% FBS, and the contents were treated for 
15min at 37°C, 42°C and 45°C    in water bath. For microscopic examinations, the plates 
were washed with PBS for 5 times and 1mL of 4% paraformaldehyde (PFA) were added 
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and kept for 15 minutes and washed with PBS for 5 times. The contents were incubated 
for 5 min with DAPI at 37°C in a 5% CO2 atmosphere to stain the nuclei (blue). The cells 
were directly imaged on a matTek well plate under an Olympus IX81 confocal 
microscope using a 100 ms exposure time with the Green Fluorescent Protein filter 
(GFP, ex/em of 475/509) and a 50 ms exposure time with the DAPI (ex/em of 358/461) 
filter at 60x APO.  
4.3.7 Quantification of liposome uptake by the macrophages 
RAW 264.7macrophages were harvested and seeded with 2 mL of cell suspension at a 
rate of (1x106 cells/mL) onto 6 well cell culture plates. Prior to the experiment, the culture 
medium was discarded and the cells were incubated with fresh serum free DMEM 
medium containing 12uL liposome/ 2 mL for 15min at 37°C, 42°Cand 45°C, then the 
culture media was discarded, and the cells were recovered by tripsinization in 15-mL 
falcon tubes. The cells were centrifuged at 1000 rpm for 5 min toremove any non-
phagocytosed liposomes, rinsed with 1x buffer, spun down, re-suspended in 100 µL of 
PBS, and subsequently the fluorescence intensity of was analyzed by FACS flow 
cytometry (BD FACS Aria, USA) with an excitation wavelength of 358/461 nm and 
analyzed with a 495/519 nm emission filter by counting 10,000 single cell events. Only 
the viable cells were gated for fluorescence analysis. The geometric mean fluorescence 
intensity of the cells was computed from the histogram plot calculated from triplicate 
data. 
4.3.8 Cytokine gene expression analysis using Real Time PCR  
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Gene expression analysis were performed for pro-inflammatory (IL1-beta, TNF-α, IL6) 
and anti-inflammatory (IL10) cytokines. 
RNA isolation and phenol chloroform RNA purification 
Total RNA was extracted using TRIZOL (Invitrogen) according to the manufacturer’s 
instructions. RNA concentration was measured using NanoDrop ND-100 followed by 
phenol chloroform RNA purification. 
Reverse Transcription Polymerase Chain Reaction (RT-PCR). cDNA synthesis was 
performed using iScript Reverse Transcription Supermix for RT-qPCR and Real Time 
RT-PCR reaction was performed using 5 times diluted cDNA. 
Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-
PCR). Relative gene expression for IL1beta, TNFalpha, IL6 and IL10, as M1 and M2 
specific cytokines was evaluated by qRT-PCR using SYBR green reagent (Eurogentec – 
qPCR Master Mix Plus for SYBR green) using AB applied Biosystem 7500 fast Real 
Time PCR instrument and indicated specific primers (Table 1). qRT-PCR data was 
analyzed by the 2(-ΔΔCT) method, using GAPDH as a reference gene.  
Table 2.qRT-PCR primers sequences  
qPCR primers Species Sequences 
mGapdh-forward Mus musculus CATCACTGCCACCCAGAAGACTG 
mGapdh-reverse Mus musculus ATGCCAGTGAGCTTCCCGTTCAG 
mTnf- alpha-forward Mus musculus CACCACCATCAAGGACTCAA 
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mTnf-alpha-reverse Mus musculus AGGCAACCTGACCACTCTCC 
mIl1-beta-forward Mus musculus TGGACCTTCCAGGATGAGGACA 
mIl1-beta-reverse Mus musculus GTTCATCTCGGAGCCTGTAGTG 
mIl6-forward Mus musculus ACAACCACGGCCTTCCCTACTT 
mIl6-reverse Mus musculus CACGATTTCCCAGAGAACATGTG 
mIl10-forward Mus musculus CGGGAAGACAATAACTGCACCC 
mIl10-reverse Mus musculus CGGTTAGCAGTATGTTGTCCAGC 
 
4.3.9. Analysis of CD86, CD206 and Cd11c Expression by Flow Cytometry 
Treated RAW 264.7macrophages were washed and re-suspended in 1xPBS containing 
2% fetal bovine serum. 100uL of cell suspension was incubated for 30 minutes with 
primary anti PE-CD86 antibody, primary anti Alexa Fluor 700-CD206 antibody and 
primary APC-CD11c antibody. Control isotype corresponding to each primary antibody 
served as control. Three washes with PBS containing 2% FBS were performed, and 
then cells were analyzed by flow cytometry with FACScalibur (BD Biosciences) at CD86, 
CD 206 and CD11C, respectively. Data was analyzed with FlowJo software, and 
represented as percentage CD86, CD206 and CD11c.  
4.3.10. Cancer cell treatment with macrophage conditioned media 
To evaluate if liposome/hyperthermia treatment of macrophages enhances cytotoxicity 
against cancer cells, 0.5*106 B16F10 melanoma cells were incubated with 100 µL of 
serum containing media at 37°C for 24hours. The cells were then rinsed, and treated 
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with conditioned media from RAW 264.7 macrophages liposome and hyperthermia 
treatment and incubated for 24 hours at 37°C in a 5% CO2 atmosphere. For comparison, 
control group without conditioned media with the same volume of serum free media were 
cultured similarly. End points were measurement of MTT assay, gene expression. 
 
4.4. RESULTS 
4.4.1 Physicochemical Characterization of Liposome   
The hydrodynamic diameter, polydispersity index, and zeta-potential of 
liposomeswasabout 180 nm, 0.132 and -4.893 mV, respectively (Table 3). 
Liposome 
Size (nm) Polydispersity Zeta potential 
mean SD mean SD mean SD 
LTSL 182.02 11.92 0.132 0.014 -4.893 4.128 
Table 3 shows the hydrodynamic diameter, polydispersity index, and zeta potential 
values of LTSLs at room temperature (25 °C). 
4.4.2. Cytotoxicity assessment of heat against macrophages 
Co-incubation of RAW 264.7 cells with liposomes and hyperthermia did not result in 
significant killing compared to liposomes, the hyperthermia or the untreated control in the 
dose range of 10 µM at 37ºC (p<0.05). For all dose ranges, the absorbance was 
comparable or higher than the untreated control indicating a lack of toxicity in 6 hours 
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incubation post-hyperthermia treatment (Fig 10a). The toxicity at the indicated dose 
range was greater in 42ºC, 45ºC than 37ºC in presence of hyperthermia (~20%).  In 
contrast, cells treated with liposome and 42ºC, 45ºC showed significant toxicity (~70%) 
in 24 hours post-hyperthermia treatment (Fig 10b) compared to untreated and 
normothermic samples in RAW 264.7 macrophage cells (p<0.05). 
 
 
Figure 10: RAW 264.7 macrophage cells cytotoxicity assessment of heat against 
macrophages after 6 hours (Fig 10a) and 24 hours (Fig 10b) of post-hyperthermia using 
MTT assay. Data are expressed as Mean ± Standard deviation.  
 
4.4.3. Cellular uptake of liposome uptake by macrophages 
Liposomes were phagocytosed successfully upon incubation with the macrophage cells 
(Fig 11a). Based on the median fluorescence intensity of liposomes, the flow cytometry 
study suggested that uptake was significantly higher in the presence of heat (~ 80%) 
51 
 




Figure 11: Cellular uptake of liposome by macrophage after 0 hours and 24 hours 
post treatment. Fig 11a-Confocal images of RAW 264.7 macrophages treated for 37ºC, 
42ºC, 45ºC for 15 minutes with bare liposomes (LTSL). Cell nucleus is stained by using 
DAPI-stained (blue), and particles are stained by coumarin-6 (C6). Fig 11b-Flow 
cytometry graphs show % positive cells for C6-LTSL fluorescent values of three 
experiments ± SD. Liposomes with 42°C hyperthermia had a significantly higher uptake 
by RAW 264.7 cells than 37C hyperthermia. 37°C hyperthermia macrophage cells were 
used as controls. 
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At 6 hours of post-treatment RAW 264.macrophage cells treated with liposome and 
hyperthermia treatment showeda significant increase in pro-inflammatory cytokine 
expression (1500-2000 fold) by liposomes compared to untreated controls (P<0.05). 
Also, compared to liposome alone, the combination of liposome/hyperthermia achieved 
a greater increase in mRNA expression, suggesting that the liposome action is 
potentiated at 42°C (Fig. 12). In contrast, increase in the expression of IL-10 was 
relatively modest (~60-fold higher), indicating that real-time combination of 
heat/liposome has a more predominant pro-inflammatory phenotype inducing property in 
mouse macrophages. Interestingly, at 45°C the presence of liposome and hyperthermia 
increased anti-inflammatory cytokine expression (IL10; 200 fold) compare to 37°C or 






Fig 12: Cytokines such as IL-1(Fig 12a), TNF-alpha(Fig 12b),IL-6(Fig 12c),IL-10(Fig 
12d) gene expression through Real Time PCR analysis on 6 hours post-treatment RAW 
264.7 macrophage cells treated with liposome and hyperthermia treatment at 37°C, 
42°C, 45°C. 
At 24 hours of post-treated RAW 264.macrophages increase in the expression of IL-10 
was relatively modest (~60-fold higher), indicating that real-time combination of 
heat/liposome has a more predominant pro-inflammatory phenotype inducing property in 
mouse macrophages. However, this was also accompanied by an expression of TNF-
alpha and IL-6 cytokines. 
4.4.5 Macrophage cell surface expression of CD86, CD206 and CD11c 
The CD86 protein expression was 3%, 30% and 10% for control, heat and liposome + 
42°C, liposome + 45°C respectively.  In contrast, the expression of CD206 increased by 
1% compared to untreated controls. These data are consistent with the gene expression 
results observed in the study described in Section 2.1.  
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When compare to the increased gene expression level of the pro-inflammatory cytokine, 
6 hours after moderate hyperthermia associated with liposome treatment, the protein 
expression of CD86, CD206 and CD11c, cell surface associated markers were 
significant increased 24 hours post treatment (Fig 13a, Fig 13b, Fig 13c), suggesting a 
delay in cell surface associated markers expression compare to cytokine expression, 
after moderate hyperthermia treatment.  
24 hours after liposome treatment at 42°C and 45°C macrophages adopted a 
combination of elongated, spindle-shaped morphology and rounded shaped morphology 
with elongated filopodia (Fig 13d). The highest morphology change, similar with a 
dendritic like cell shape, has been noticed in 24 hours after 42°C and 45°C treatment in 
the presence of liposome. 
Furthermore, the change in cell morphology has been associated with a significant 
increase of CD11c surface marker 24 hours after 42°C and 45°C treatment in the 
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Figure 13: Assessment of M1 and M2 macrophages on cell surface by flow cytometry. 
LTSL and 37°C, 42°C, 45°C hyperthermia treated RAW 264.7 macrophages was stained 
for CD8, CD206 and CD11c. Number of macrophages that stained positively for each 
antigen were counted and expressed as percentage of CD86(Fig 13a), CD206(Fig 
13b),CD11c(Fig 13c) macrophage cells and presence of dendritic phenotype(Fig 13e). 
4.4.6 Cytotoxicity against melanoma cells 
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Co-incubation of B16F10 melanoma cells with conditioned media from RAW 264.7 
macrophages treated with liposome and hyperthermia treatment after 24 hours did not 
result in significant killing compared to control (p<0.05). The cell viability was greater in 6 
hours conditioned media liposome treatment (Fig 14a). In contrast, the cell death was 
significant ~30%   in 24 hours conditioned media harvested from liposome treatment (Fig 
14b) compared to untreated samples (p<0.05).  
 
Figure 14: B16F10 cells cytotoxicity assessment of heat against macrophages after 6 
hours (Fig 14a) and 24 hours (Fig 14b) of conditioned media from RAW 264.7 
macrophages using MTT assay. Data are expressed as Mean ± Standard deviation.  
4.5 Discussion 
The tumor microenvironment is characterized by the presence of inflammatory cells such 
as macrophages and lymphocytes. These cells play an important role in carcinogenesis 
and suppression of antitumor immunity (Choi, Gyamfi et al. 2017). Of these, 
macrophages are the major component of leucocyte population and form approximately 
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50% of tumor mass (Vinogradov, Warren et al. 2014). Macrophages are typically 
hypothesized to originate from blood compartments, and exist in two distinct polarized 
phenotypes in tumors: M1 (classical activated) and M2 (alternatively activated pro-
tumor)(Mantovani, Marchesi et al. 2017). Several preclinical and clinical studies have 
established that a high population of M2 macrophages in the tumors is associated with 
poor patient survival (Goswami, Ghosh et al. 2017). A variety of mechanisms triggers an 
M2 like phenotype in the tumor microenvironment. These include hypoxic and lactate 
microenvironment, a negative regulation by tumor necrosis factor (TNF), and the 
presence of anti-inflammatory cytokines driving M2 polarization (IL-4, IL10, and IL-13) 
(Kratochvill, Neale et al. 2015). In particular, the increased production of IL-10 correlates 
strongly with M2 specific cell surface expression of CD206 (Roszer 2015). These 
activation pathways impact chemotherapy delivery by affecting vascular leakage and 
also induce chemo resistance through the release of milk fat globule-epidermal growth 
factor 8 protein (MFG-E8) and subsequent activation of STAT3 to provides survival 
signals for tumor-initiating/cancer stem cells (CSCs) (De Palma and Lewis 2013). Thus, 
overcoming the M2 rich macrophage population in tumors can be a critical link in 
theimprovement of cancer chemo- and immuno-therapy. 
One approach to overcome pro-humoral M2 phenotype can be by harnessing the high 
plasticity of macrophages to re-educate them towards a tumor-suppressive M1 
phenotype using nanoparticles. Classically activated M1 macrophages secrete cytokines 
such as TNF, IL-1, IL-6, IL-8, and IL-12 to increase vascular permeability and 
recruitment of inflammatory cells in the tumor(Arango Duque and Descoteaux 2014). A 
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high M1/M2 ratio of macrophages directly induces cancer cell killing and is known to 
enhance survival in patients (e.g. ovarian tumors) (Zhang, He et al. 2014). To leverage 
these benefits, Wang et al. developed a tumor microenvironment-responsive poly (β-
amino ester) encapsulated with IL-12 for passive accumulation in the tumor 
microenvironment. The releaseof IL-12 from the nanoparticles enhanced M1 specific cell 
surface expression and superior treatment responses (Wang, Lin et al. 2017). Similarly, 
Zanganeh et al. found that iron supplement ferumoxytol enhanced M1 phenotype via 
enhancement of caspase-3 and pro-inflammatory Th1 activity. This methodology also 
induced regression of subcutaneous adenocarcinomas in mice model (Zanganeh, Hutter 
et al. 2016). Based on these promising observations, we hypothesized that 
liposome/hyperthermia combination can synergistically modulate macrophage 
polarization dynamics. The use of liposomes is especially attractive since they are 
biodegradable and demonstrate a high degree of membrane stability that is essential for 
tumor accumulation (Meers, Neville et al. 2008). Liposomes are also adaptable for 
externally-triggered, localized release of drug payloads using hyperthermia (40-45ºC) 
(Negussie, Yarmolenko et al. 2010, Partanen, Yarmolenko et al. 2012, Ranjan, Jacobs 
et al. 2012). Hyperthermia alone can induce expression of higher levels of MICA, an 
NKG2D ligand for NK or CD8+ T cells mediated tumor lysis (Toraya-Brown, Sheen et al. 
2014). Thus, the combination of liposomes and hyperthermia potentially can result in a 
qualitatively new and integrated intervention that, if successful, can be translated to 
clinical application for both T-cell and macrophage modulated immunotherapy. 
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Nanoparticles are recognized as foreign particulate material and are phagocytosed by 
the tumor macrophages (Vinogradov, Warren et al. 2014). Typically, larger particles 
(100-1000µM) with low negative to positive charge demonstrate a more efficient 
endocytosis by the macrophages (Lee, Hwang et al. 2015). In this study, we aimed to 
attain a hydrodynamic size of 100-200 nm with low negative zeta potential for the 
liposomes to obtain endocytosis using the RAW264.7 murine macrophage cell line as a 
model. Confocal study confirmed that our formulation chemistry caused efficient cellular 
uptake in the endosomal and cytosolic compartment of the cells (Fig. 11a). Quantitative 
estimation of uptake rate by flow cytometry showed a relative greater (Fig. 11b) at 42ºC 
compared to 37ºC presumable due to the high metabolic competency of cells.  As 
temperature increased from 42 to 45ºC, the uptake rates decreased probably due to 
poor survival of macrophages. This suggests that optimal temperature range for 
macrophage survival in tumors is quite narrow and require discreet control. An 
unexpected but surprising finding was the transition of macrophages towards a dendritic 
cell like phenotype at a higher temperature. This was evidenced by the high cell surface 
expression of CD11c and presence of dendritic phenotype (Fig. 13e). Studies are 
currently underway in the lab to understand the mechanism; however, the obtained data 
clearly suggest that the macrophages demonstrate a high temperature dependency in 
their plasticity. Additionally, the presence and intracellular uptake of liposomes 
dramatically impact gene expression to potentiate hyperthermia mediated responses. 
We also speculate that uptake of nanoparticles by the macrophages regardless of 
particle chemistry is the rate-limiting step for induction of cellular polarization.  This is 
because our gene expression data with liposomes are in line with the previous 
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observation of Zanganeh et al. study that employed iron-oxide nanoparticles. In general, 
the main pro-inflammatory cytokines, IL1 beta, and TNF-α, were significantly increased 
and the specific anti-inflammatory markers, such as IL-10 were significantly decreased 
compared to untreated controls. Notably, the gene expression was not necessarily 
accompanied with cell surface expression; however, this process still resulted in 
significantly enhanced cancer cell cytotoxicity. In summary, nanoparticle induced 
responses are potentiated by heat induced cellular stress that causes differential gene 
expression, and this approach may serve as an important therapeutic component of 
macrophage-modulated cancer immunotherapies.  
Our in vitro study has several limitations. The tumor microenvironment is much more 
complex in vivo due to the involvement of factors and signals mediated by the tumor 
cells and immunosuppressive immune cells and fibroblasts, which can impact 
macrophage polarization. In addition, immunosuppressors like myeloid-derived 
suppressor cells (MDSC), regulatory T cells, and factors like fibroblast growth factor, 
vascular endothelial growth factor, and tumor promoting cytokines may impact induction 
of M1 specific genes. The goal of our in vitro investigation was to specifically delineate 
the role of hyperthermia/nanoparticle therapy on macrophages. In future, we will perform 
timed analyses of T-cell, MDSCs, and cytokines in tumor and lymphoid organs like 
spleen and lymph nodes to assess such mechanisms in more detail. Another limitation 
of our work was a lack of long-lasting enhancement of the pro-inflammatory phenotype 
and anti-tumoral immune effect with heat. This is addressable clinically with more 
frequent treatments to induce greater regression.  
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In conclusion, our novel concept of liposome combined hyperthermia therapy of 
macrophages provides new insights on ways to spatially control the macrophage 
polarization and plasticity within tumors. To our best knowledge, the induction of 
macrophage polarization with liposomes has not been shown before, and their role in 
tumors has so far been largely limited to cell depot of drugs. Thus, we believe that 
elucidation of the alternative benefits of liposome with hyperthermia will eventually 
improve immunotherapies within the tumor microenvironment. This may lead to 
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